Study Evaluating Single Doses of GAP-134

NCT00820521 ↗

Phase 1 Withdrawn Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedSingle-groupTriple-blindTreatment

Summary

The purpose of this study is to assess the safety and tolerability of ascending single oral doses of GAP-134 in healthy subjects, to provide the initial pharmacokinetic profile of the oral formulation of GAP-134 in healthy subjects, and to evaluate the effect on the pharmacokinetic profile of a high-fat meal of 450 mg of GAP-134 administered to healthy subjects.

Timeline

Start: 2009-02
Primary completion: 2009-04
Completion: 2009-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Danegaptide	Peptide	450 mg	Oral

Indications

No indication recorded.